Jaime Sanders has suffered from migraines since she was eight-years-old. Despite her chronic pain, she has “always managed to find the strength and will to move forward in life.” Sanders, a patient advocate and blogger, was joined by experts in different areas of migraine research and treatment to discuss the societal burden of this debilitating disease during a Research!America Capitol Hill briefing on June 15, 2017.
Walter Koroshetz, M.D., director of the National Institute of Neurological Disorders and Stroke (NINDS), emphasized how the BRAIN initiative and current research have made significant progress in identifying causes of migraines. The research has led to a treatment currently under review at the Food and Drug Administration, he said. However, more research is needed not only to understand the molecular causes, but to learn and address disparities associated with this condition. “African American women have 27% more frequent headaches than Caucasian women,” he noted.
Amaal Starling, M.D., an associate professor and physician at the Mayo Clinic, noted the lack of funding for migraine research and physicians to treat patients. While 40 million Americans suffer from migraines, there are only 520 headache specialists in the U.S., she said.
“We need to get that word out and encourage new physicians to go into headache medicine," added Mary Franklin, executive director of the National Headache Foundation who moderated the panel.
Dr. Starling said lack of funding leads to gaps in care. “Migraine is not just a headache. Migraine is a neurologic disease that deserves funding based on disease burden,” Starling said. More funding, she added, will give scientists and physicians the opportunity to research new treatment options.
As an adult, Sanders said she still suffers from the stigma associated with migraine which affects women disproportionately as well as veterans and children. "Migraine is as diverse a disorder as the people who occupy this planet. Not one migraine patient looks the same as the other," she stressed.
Brian Gifford, Ph.D., a researcher at the Integrated Benefits Institute, discussed the burden of migraine in the workplace. He estimates there is a $20 billion loss to employers on health care spending and productivity due to migraine.
The condition is not adequately addressed in the workplace, he said, further complicating efforts for migraine sufferers to effectively treat and manage their illness.
For photos of the event, click here(link is external).
Caitlin Grzeskowiak is a Research!America Communications Intern.
Among collegiate student-athletes with a history of concussion, almost one in three males and nearly one half of females reported having a history of migraine, according to a new report. But the researchers cautioned that the data are insufficient to support any relationship between sport-related concussions and migraines or other headaches.
Read more at Neurology Today.
For chronic migraine patients, the only thing better than making a headache stop is preventing it altogether. And new research suggests that patients may soon have new options for doing just that.
Phase III clinical trials for a biologic drug called “fremanezumab” show promising results, the pharmaceutical manufacturer Teva announced last week. The therapy provided a statistically significant reduction in the number of headache days that trial participants experienced during the month following initial dosing. Patients also demonstrated improvement in response rate and efficacy. Responses were compared against placebo.
The drug targets calcitonin gene-related peptide, or CGRP, which is involved in the experience of migraine pain. Several other variations of CGRP inhibitor drugs are also in development, though fremanezumab is the first to demonstrate efficacy for quarterly dosing.
Migraine is most often experienced as a severe, throbbing headache accompanied by vision disturbances and, for some, vomiting, nausea, and sensitivity to light and sound. Nearly one in every four U.S. households includes someone with migraine. The disease disproportionately affects women and is number one cause of neurological disability in the United States.
“CGRP drugs could allow patients to reclaim control over their day-to-day lives, limiting migraine’s ability to disrupt their work and interfere with their family responsibilities,” noted Lindsay Videnieks, director of the Headache and Migraine Policy Forum. “We urge regulators to give these therapies their full consideration in a timely manner.”
The drug’s manufacturer plans to submit a Biologics License Application to the U.S. Food and Drug Administration later this year.
BOSTON — More than 1,000 migraine and headache specialists from around the world will gather in Boston this week to present the latest data on new therapies for headache disorders.
The American Headache Society's 59th annual scientific meeting will be held Thursday through Sunday at the Westin Boston Waterfront Hotel.
Read more at The Boston Herald.
Watch how Tom Sayen is committed to serving his friends and his community despite chronic intractable migraines.
It's likely we know someone who suffers from the debilitating pain of migraines. Symptoms of the headaches, such as sensitivity to sound, light, or touch, tingling or numbness, or vision changes, can make going to work, spending time with family, or even eating nearly impossible. Now, researchers at the University of Toronto, Canada, found migraine attacks double the risk of developing generalized anxiety disorders in men.
Read more at Medical Daily.
“Wearing sunglasses indoors is increasing your sensitivity to light.” My wife and I were floored when her headache specialist made this statement. Chronic migraine had made her so sensitive to light that she had to wear sunglasses indoors. During an attack, photophobia increased her misery. Sunlight, light from computer monitors and TVs, and fluorescent lights triggered even more attacks.
Read more at National Headache Foundation.
Learn how Barbara Monette has used art to cope with chronic migraines for nearly a decade
Move Against Migraine illustrates the hidden truth about migraine
FOR IMMEDIATE RELEASE: [MOUNT ROYAL, NJ, March 20, 2017] – The American Migraine Foundation (AMF) announced today that it is launching an initiative – Move Against Migraine – to empower the more than 36 million Americans living with migraine to advocate for themselves to find the support and treatment they need. Given the lack of awareness of the varied symptoms that can occur during migraine attacks and the long-standing stigma associated with this disease, less than 5% of those with the most debilitating form of migraine have sought help, received a diagnosis, and been treated.
Read More at American Migraine Foundation.
Chronic migraine is seldom a lone condition, explains a new white paper from the Headache & Migraine Policy Forum. And when chronic migraine patients suffer from common comorbidities such as depression or hypertension, their medical costs rise while their productivity suffers.
Authored by former Department of Health and Human Services official Kenneth E. Thorpe, Ph.D., the paper is entitled “Prevalence, Health Care Spending and Comorbidities Associated with Chronic Migraine Patients.” It captures analysis of 2008-2013 Medical Expenditure Panel Surveys, which are conducted by the Agency for Healthcare Research and Quality.
Key findings include:
Prevalence. Chronic migraine sufferers are predominantly urban, white and female – working full time and living in the South.
Comorbidities. Nearly 90 percent of chronic migraine patients have at least one other chronic condition. The most common include depression and anxiety; hypertension; and arthritis.
Cost. The cost of treating patients with chronic migraine and additional chronic diseases is eight times higher than the cost of treating patients with only chronic migraine. Likewise, the cost of treating conditions such as arthritis, depression, anxiety and diabetes is higher if the patient being treated also suffers from chronic migraine.
Productivity. More than 20 percent of chronic migraine sufferers are disabled. That figure rises as the number of comorbid conditions increases.
The paper argues that these findings justify “whole-person care,” a point that Dr. Thorpe reiterated at Tuesday’s Capitol Hill policy forum sponsored by the Headache & Migraine Policy Forum. “If you’re really treating these conditions simultaneously and interactively,” Dr. Thorpe explained, “you’re going to get better outcomes across the board.” The approach could yield “substantial health dividends,” the paper notes.
The Headache & Migraine Policy Forum advances public policies that promote accelerated innovation and improved treatments for headache and migraine sufferers.
The event coincided with the 10th annual Headache on the Hill, an advocacy effort organized by the Alliance for Headache Disorders Advocacy. Headache on the Hill brings more than 125 health professionals, migraine advocates and patients to Capitol Hill to raise awareness about the impact of headache and migraine disorders and to seek increased research funding.
The paper extends the current body of research in several directions:
• First, we provide more recent prevalence estimates of chronic migraine.
• Second, we examine the medical treatment costs by source of care and the prevalence of the use of different sources of care.
• Third, we examine the prevalence of comorbid conditions and their financial treatment and workplace productivity implications.
• Finally, we examine the impact that chronic migraine has on the treatment costs of patients with both chronic migraine and other comorbid conditions.
Read the full paper here.
We devote vast resources to intensive, one-off procedures, while starving the kind of steady, intimate care that often helps people more.
By 2010, Bill Haynes had spent almost four decades under attack from the inside of his skull. He was fifty-seven years old, and he suffered from severe migraines that felt as if a drill were working behind his eyes, across his forehead, and down the back of his head and neck. They left him nauseated, causing him to vomit every half hour for up to eighteen hours. He’d spend a day and a half in bed, and then another day stumbling through sentences. The pain would gradually subside, but often not entirely. And after a few days a new attack would begin....
He saw all kinds of doctors—primary-care physicians, neurologists, psychiatrists—who told him what he already knew: he had chronic migraine headaches. And what little the doctors had to offer didn’t do him much good. Headaches rank among the most common reasons for doctor visits worldwide. A small number are due to secondary causes, such as a brain tumor, cerebral aneurysm, head injury, or infection. Most are tension headaches—diffuse, muscle-related head pain with a tightening, non-pulsating quality—that generally respond to analgesics, sleep, neck exercises, and time. Migraines afflict about ten per cent of people with headaches, but a much larger percentage of those who see doctors, because migraines are difficult to control.
Read more at the New Yorker
Balanced pain management offers an opportunity to better manage pain, control rising costs and reduce the potential for opioid abuse, explains a new white paper from the Alliance for Balanced Pain Management. But realizing the benefits of a balanced approach requires policymakers and insurers to first expand access to more personalized, comprehensive treatments.
More at Institute for Patient Access
During today’s annual Headache on the Hill event, patients, physicians and advocates from the Alliance for Headache Disorders Advocacy will once again brief members of Congress on the impact of headache – and how better funding, more research and improved access to treatments could mitigate the conditions’ impact on patients.
Headache disorders affect an estimated 90 percent of Americans, while migraine plagues 36 million Americans each year. Cluster headaches, characterized by their severe pain, are now as prevalent as multiple sclerosis.
More at Institute for Patient Access
Far more than an occasional nuisance, headaches interfere with countless Americans’ daily lives – and cost the country $31 billion annually. Yet the National Institutes of Health funding for headache disorders research pales in comparison to funding for less widespread conditions. This apparent discrepancy was central among the concerns expressed by the physician and patient advocates convening today for Alliance for Headache Disorders Advocacy’s seventh annual Headache on the Hill in Washington, DC.
More at Institute for Patient Access